Clinical trials for first lung cancer vaccine underway. Where in Va. and Md. is it being tested
A vaccine, BNT116 by BioNTech, targeting non-small cell lung cancer (NSCLC) is being tested in Maryland and Virginia, aiming to eliminate cancer cells and prevent recurrence through a global clinical trial. Using mRNA technology, it trains the immune system to recognize and attack NSCLC-specific tumor markers. The trial, recruiting participants in the D.C. region, will test BNT116's efficacy alone and with chemotherapy/immunotherapy, aiming to prevent lung cancer recurrence.
Related Clinical Trials
Highlighted Terms
Related News
Clinical trials of mRNA vaccine BNT116 against non-small cell lung cancer have started in seven countries, involving 130 patients receiving the vaccine with immunotherapy. The vaccine uses mRNA to present tumor markers to the immune system, aiming to enhance cancer-specific immune responses without affecting healthy cells.
A vaccine, BNT116 by BioNTech, targeting non-small cell lung cancer (NSCLC) is being tested in Maryland and Virginia, aiming to eliminate cancer cells and prevent recurrence through a global clinical trial. Using mRNA technology, it trains the immune system to recognize and attack NSCLC-specific tumor markers. The trial, recruiting participants in the D.C. region, will test BNT116's efficacy alone and with chemotherapy/immunotherapy, aiming to prevent lung cancer recurrence.